Top Markets
#1 Purr Purr +59.29%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +32.91%
#4 Kinetiq Kinetiq +30.53%
#5 ApeX ApeX +25.45%
#6 Non-Playable Coin Non-Playable Coin +21.19%
#7 OriginTrail OriginTrail +19.37%
#8 Morpho Morpho +18.34%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.17%
#10 Fake World Assets Fake World Assets +18.14%
Coin of the day
Purr Purr
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CANbridge Pharmaceuticals Inc. CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc.

1228
Classifica tra le azioni #21199
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the... CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Prezzo delle azioni
$0.26544693
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$112.77M
Variazione (1 giorno)
-0.72%
Variazione (1 anno)
-16.36%
Paese
CN
Scambia CANbridge Pharmaceuticals Inc. (1228)

Categoria

Healthcare
Ricavi di CANbridge Pharmaceuticals Inc. (1228)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di CANbridge Pharmaceuticals Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per CANbridge Pharmaceuticals Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH